%0 Journal Article
%T Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy
%J -
%D 2019
%R https://doi.org/10.1016/j.ccell.2019.01.003
%X £¿ Activated T cell signatures/populations drive response to anti-PD-1-based therapies £¿ EOMES +CD69 +CD45RO + effector memory T cells are associated with response £¿ EOMES +CD69 +CD45RO + expression is associated with longer PFS and tumor shrinkage £¿ Non-responders with TIL-hot tumors express other immune drug target
%U https://www.cell.com/cancer-cell/fulltext/S1535-6108(19)30037-6